Imaging angiogenesis;Bildgebung von angiogenese

Radiologe

Volumn 41, Issue 2, 2001, Pages 138-145

  Bremer, C ^a   Bogdanov, A A ^a   Weissleder, R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Angiogenesis; Anti angiogenic treatment; Imaging

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; ACIDIC FIBROBLAST GROWTH FACTOR; AE 941; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANGIOGENIN; ANGIOSTATIN; BASIC FIBROBLAST GROWTH FACTOR; ENDOSTATIN; GADOLINIUM PENTETATE; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; IM 862; INTERLEUKIN 12; INTERLEUKIN 8; MARIMASTAT; PLATELET DERIVED GROWTH FACTOR; PRINOMASTAT; PROLACTIN; REBIMASTAT; SQUALAMINE; THALIDOMIDE; THROMBOCYTE FACTOR 4; THROMBOSPONDIN 1; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; DIAGNOSTIC IMAGING; GROWTH REGULATION; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; SHORT SURVEY; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; DIAGNOSTIC IMAGING; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0035118919     PISSN: 0033832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001170050956     Document Type: Short Survey

References (52)

1. Tumor angiogenesis: Therapeutic implications
2. Isolation of a tumor factor responsible or angiogenesis
3. Angiogenesis in cancer, vascular, rheumatoid and other disease
4. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
5. Angiogenesis in embryos and ischemic diseases
6. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
7. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis
8. Analysis of experimental antiangiogenic therapy
9. Treatment of pulmonary hemangiomatosis with recombinant interferon alfa- 2a
10. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
11. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
12. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma
13. Intratumor microvessel density as a prognostic factor in cancer
14. Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma
15. Determinants of tumor blood flow: A review
16. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours
17. Serum basic fibroblast growth factor in men with and without prostate carcinoma
18. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers
19. Approaches and agents for imaging the vascular system
20. Optimization of iron oxides for contrast enhanced MRA: Results of an experimental study
21. RES-specific imaging of the liver and spleen with iron oxide particles designed for blood pool MR-angiography
22. Dynamic functional imaging of relative cerebral blood volume during rat forepaw stimulation
23. Fast MRI contrast medium dynamics for characterization of tumors. Experiences with functional MR-mammography
24. Correlation between contrast enhancement in dynamic magnetic resonance imaging of the breast and tumor angiogenesis
25. Assessment of tumor microcirculation: A new role of dynamic contrast MR imaging
26. Angiogenesis of cervix carcinoma. Contrast enhanced dynamic MRI, histologic quantification of capillary density and lymphatic system infiltration
27. Breast lesions: Correlation of contrast medium enhancement patterns on MR images with histopathologic findings and tumor angiogenesis
28. Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI
29. Benign and malignant breast lesions: Differentiation with echo-planar MR imaging
30. Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: Comparison of macromolecular and small-molecular contrast media
31. Continuous assessment of perfusion by tagging including volume and water extraction (CAPTIVE): A steady-state contrast agent technique for measuring blood flow, relative blood volume fraction, and the water extraction fraction
32. MR perfusion studies with T1-weighted echo planar imaging
33. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: Status report
34. Pathophysiologic basis of contrast enhancement in breast tumors
35. Methodological approaches to quantitative evaluation of microcirculation in tissues with dynamic magnetic resonance tomography
36. Non-invasive vascular imaging: Assessing tumour vascularity
37. Uterine cervical carcinoma: Comparison of standard and pharmacokinetic analysis of time-intensity curves for assessment of tumor angiogenesis and patient survival
38. Assessing tumor angiogenesis using macromolecular MR imaging contrast media
39. Size optimization of synthetic graft copolymers for in vivo angiogenesis imaging
40. Non-invasive in vivo mapping of tumor and interstitial volume fractions non-invasively
41. In vivo assessment of vascular endothelial growth factor-induced angiogenesis
42. NMR imaging of changes in vascular morphology due to tumor angiogenesis
43. MR contrast due to intravascular magnetic susceptibility perturbations
44. Measurement of vascular volume in experimental rat tumors by 19F magnetic resonance imaging
45. Measurement of vascular volume fraction and blood-tissue permeability constants with a pharmacokinetic model: Studies in rat muscle tumors with dynamic Gd-DTPA enhanced MRI
46. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging
47. Targeting by affinity-matured recombinant antibody fragments of an angiogenesis associated fibronectin isoform
48. Imaging of tumour neovasculature by targeting the TGF-beta binding receptor endoglin
49. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes
50. In vivo molecular target assessment of MMP inhibition
51. Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor
52. Treatment of experimental brain tumors with trombospondin-1 derived peptides: An in vivo imaging study